Health Care Innovation
Commentary
The Private Sector Is Setting The PACE For Managed Care
Rising demand for long-term care is inevitable as more and more baby boomers retire. Meeting this demand will be a challenge. Recent evidence from the PACE program demonstrates that for-profit care providers can help meet this growing demand, but only if the regulatory environment allows it. Read the op-ed here.
Blog
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Commentary
Republicans’ Free Chance To Save Sick Kids
Right now, Congress has a chance to save the lives of countless sick children—without spending a dime of taxpayer money. It could seize that opportunity by reauthorizing the Pediatric Priority Review Voucher (PPRV) program—which incentivizes companies to invest in lifesaving but financially risky treatments for rare pediatric diseases. Read the ...
Commentary
In defense of Medicaid work requirements
Republicans are considering cuts to Medicaid, the joint federal-state health plan that provides taxpayer-funded health coverage to 80 million adults and children. Many in the GOP would like to require able-bodied Medicaid beneficiaries to work in exchange for coverage. That’s a good idea. Read the entire op-ed here.
Commentary
Make Telehealth Coverage a Permanent Medicare Feature
When the Trump administration loosened telemedicine restrictions for Medicare patients in March 2020, the move was seen as temporary. The COVID-19 pandemic was in its early days. Read the op-ed here:
Biosimilars
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
Commentary
RFK Jr. Can Breathe New Life Into HHS
Speaking to agency staffers last week, newly installed Secretary of Health and Human Services Robert F. Kennedy, Jr., insisted that “nothing is off limits” in his fight against chronic disease. It’s an encouraging message. HHS is in desperate need of modernization. Read the entire op-ed in Newsmax.
Commentary
RFK Jr.’s Confirmation Hearings Can’t Leave This Question Unanswered
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services. RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people ...
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Commentary
A Year Later, Florida’s Drug Importation Plan Is Misguided As Ever
When president-elect Donald Trump joked about making Canada the 51st state, he had an unlikely supporter: Bernie Sanders. “Does that mean that we can adopt the Canadian health care system and . . . lower the cost of prescription drugs,” the Vermont senator wrote on X. “I’m all for it.” ...
The Private Sector Is Setting The PACE For Managed Care
Rising demand for long-term care is inevitable as more and more baby boomers retire. Meeting this demand will be a challenge. Recent evidence from the PACE program demonstrates that for-profit care providers can help meet this growing demand, but only if the regulatory environment allows it. Read the op-ed here.
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Republicans’ Free Chance To Save Sick Kids
Right now, Congress has a chance to save the lives of countless sick children—without spending a dime of taxpayer money. It could seize that opportunity by reauthorizing the Pediatric Priority Review Voucher (PPRV) program—which incentivizes companies to invest in lifesaving but financially risky treatments for rare pediatric diseases. Read the ...
In defense of Medicaid work requirements
Republicans are considering cuts to Medicaid, the joint federal-state health plan that provides taxpayer-funded health coverage to 80 million adults and children. Many in the GOP would like to require able-bodied Medicaid beneficiaries to work in exchange for coverage. That’s a good idea. Read the entire op-ed here.
Make Telehealth Coverage a Permanent Medicare Feature
When the Trump administration loosened telemedicine restrictions for Medicare patients in March 2020, the move was seen as temporary. The COVID-19 pandemic was in its early days. Read the op-ed here:
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
RFK Jr. Can Breathe New Life Into HHS
Speaking to agency staffers last week, newly installed Secretary of Health and Human Services Robert F. Kennedy, Jr., insisted that “nothing is off limits” in his fight against chronic disease. It’s an encouraging message. HHS is in desperate need of modernization. Read the entire op-ed in Newsmax.
RFK Jr.’s Confirmation Hearings Can’t Leave This Question Unanswered
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services. RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
A Year Later, Florida’s Drug Importation Plan Is Misguided As Ever
When president-elect Donald Trump joked about making Canada the 51st state, he had an unlikely supporter: Bernie Sanders. “Does that mean that we can adopt the Canadian health care system and . . . lower the cost of prescription drugs,” the Vermont senator wrote on X. “I’m all for it.” ...
